A case of surgically treated peristomal pyoderma gangrenosum in a patient with rheumatoid arthritis

Cutaneous manifestations in patients with rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with different extra-articular manifestations. Among those extra-articular manifestations, there are significant cutaneous manifestations which may result in first admission to a dermatologist. In this article some specific and non-specific skin lesions of RA such as rheumatoid nodules, exacerbated nodules, rheumatoid vascu...

Case closed: An economical treatment protocol for peristomal skin excoriation.

Introduction Approximately 45% of stoma patients experience peristomal skin excoriation.1 Common causes include mechanical trauma, infectious dermatitis, and pyoderma gangrenosum. Pyoderma gangrenosum most often is associated with inflammatory bowel disease; presentation may begin with mild excoriation that rapidly develops into painful, pyogenic ulcers within hours or days. Regardless of the c...

A Case of Pyoderma Gangrenosum in a Patient with Rheumatoid Arthritis Treated with Abatacept.

Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.

Pyoderma gangrenosum (PG) is characterized by ulcerative skin lesions. Infliximab (IFX) may promote PG healing in patients with inflammatory bowel disease, but whether IFX is effective for treating PG in patients with rheumatoid arthritis (RA) has not reported. We report the case of a 53-year-old woman with PG complicated by RA who was treated using IFX therapy. This case suggests that IFX ther...

Intravenous immunoglobulin use in managing severe, perioperative peristomal pyoderma gangrenosum following subtotal colectomy with end ileostomy for medically refractory chronic ulcerative colitis

Peristomal pyoderma gangrenosum (PPG) is a rare subtype of pyoderma gangrenosum that is characterized by painful, necrotic ulcerations occurring in the area surrounding an abdominal stoma. PPG is typically seen in younger patients with active inflammatory bowel disease. The etiology and pathogenesis is largely unknown and risk factors are not well defined. Therapy typically involves a combinati...